Esperion Therapeutics (NASDAQ:ESPR) executives told investors the company delivered its “strongest performance to date” in ...

About one-third of U.S. adults take a daily multivitamin, often to fill nutritional gaps or as a form of “insurance.” While ...

Executives from Esperion Therapeutics (NASDAQ:ESPR) highlighted accelerating revenue growth, plans to expand its commercial ...

Detailed price information for Esperion Theraptc (ESPR-Q) from The Globe and Mail including charting and trades.

Heart Failure showed that despite a decreased diuretic response in patients with acute decompensated heart failure (ADHF), in ...

A secondary analysis of the SOUL trial shows significant improvement in heart failure outcomes with oral semaglutide vs placebo, consistent with the injectable formulation.

Yet another possibility is that the brain’s habit systems have become very strong, and you—or they—could be entering ...

Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, a privately held biopharmaceutical company. The acquisition focuses on the integration of Enbumyst™ ...

ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing ...

A novel risk calculator integrating comorbidities and gut-derived biomarkers stratifies risk of rehospitalisation and death in heart failure.

Despite substantial advances in guideline-directed medical therapy, recurrent hospitalization remains a persistent challenge in the management of congestive heart failure (CHF). Fluid overload is ...